Progress of MCL-1 and its inhibitors in hematologic malignancies

doi:10.3760/cma.j.cn371439-20230612-00018

Abstract

Abstract:

Myeloid cell leukemia-1 （MCL-1）is an anti-apoptotic protein that plays a key role in promoting cell survival in multiple myeloma，acute myeloid leukemia and non-Hodgkin lymphoma. MCL-1 is highly expressed in a variety of hematological malignancies，which is one of the important factors leading to poor prognosis and chemoresistance in patients with hematological malignancies. Therefore，MCL-1 is an important therapeutic target for hematological malignancies. Several MCL-1 inhibitors have entered clinical trials，including S63845，AZD5991，S64315，AMG-176，and AMG-397. The treatment plans used for hematological malignancies include monotherapy with MCL-1 inhibitors，as well as combination therapy with B cell lymphoma 2 inhibitors or immunomodulatory drugs，all indicating that MCL-1 inhibitors may be a breakthrough point for targeted treatment of hematological malignancies.

Key words: Hematologic neoplasms, Myeloid cell leukemia-1, Inhibitor

Teng Yuan, Li Lijuan, Zhang Liansheng. Progress of MCL-1 and its inhibitors in hematologic malignancies[J]. Journal of International Oncology, 2024, 51(2): 119-122.

References 35

[1]	Gupta VA, Ackley J, Kaufman JL, et al. BCL2 family inhibitors in the biology and treatment of multiple myeloma[J]. Blood Lymphat Cancer, 2021, 11: 11-24. DOI: 10.2147/BLCTT.S245191. pmid: 33737856
[2]	Wei AH, Roberts AW, Spencer A, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress[J]. Blood Rev, 2020, 44: 100672. DOI: 10.1016/j.blre.2020.100672.
[3]	Slomp A, Moesbergen LM, Gong JN, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting[J]. Blood Adv, 2019, 3(24): 4202-4214. DOI: 10.1182/bloodadvances.2019000702. pmid: 31856269
[4]	Gupta VA, Matulis SM, Conage-Pough JE, et al. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma[J]. Blood, 2017, 129(14): 1969-1979. DOI: 10.1182/blood-2016-10-745059. pmid: 28151428
[5]	Algarín EM, Quwaider D, Campos-Laborie FJ, et al. Stroma-mediated resistance to S63845 and venetoclax through MCL-1 and BCL-2 expression changes induced by miR-193b-3p and miR-21-5p dysregulation in multiple myeloma[J]. Cells, 2021, 10(3): 559. DOI: 10.3390/cells10030559.
[6]	Gomez-Bougie P, Maiga S, Tessoulin B, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment[J]. Blood, 2018, 132(25): 2656-2669. DOI: 10.1182/blood-2018-03-836718. pmid: 30309889
[7]	Algarín EM, Díaz-Tejedor A, Mogollón P, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma[J]. Haematologica, 2020, 105(3): e116-e120. DOI: 10.3324/haematol.2018.212308.
[8]	Tagoug A, Safra I. The impact of panobinostat on cell death in combination with S63845 in multiple myeloma cells[J]. Indian J Hematol Blood Transfus, 2023, 39(2): 245-257. DOI: 10.1007/s12288-022-01584-4.
[9]	Szlávik Z, Ondi L, Csékei M, et al. Structure-guided discovery of a selective Mcl-1 inhibitor with cellular activity[J]. J Med Chem, 2019, 62(15): 6913-6924. DOI: 10.1021/acs.jmedchem.9b00134. pmid: 31339316
[10]	ClinicalTrials. gov. Phase Ⅰ study of MIK665, a Mcl-1 inhibitor, in patients with refractory or relapsed lymphoma or multiple myeloma[EB/OL]. (2021-08-03)[2023-05-18]. https://classic.clinicaltrials.gov/ct2/show/NCT02992483.
[11]	Kadia TM, Kantarjian HM, Konopleva M. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy[J]. Oncotarget, 2019, 10(12): 1250-1265. DOI: 10.18632/oncotarget.26579. pmid: 30815228
[12]	Ewald L, Dittmann J, Vogler M, et al. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML[J]. Cell Death Dis, 2019, 10(12): 917. DOI: 10.1038/s41419-019-2156-2. pmid: 31801941
[13]	Zhang Q, Riley-Gillis B, Han L, et al. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia[J]. Signal Transduct Target Ther, 2022, 7(1): 51. DOI: 10.1038/s41392-021-00870-3.
[14]	Wang Q, Hao S. A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML[J]. Oncol Lett, 2019, 18(5): 5481-5489. DOI: 10.3892/ol.2019.10891. pmid: 31612056
[15]	Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia[J]. Nat Commun, 2018, 9(1): 5341. DOI: 10.1038/s41467-018-07551-w. pmid: 30559424
[16]	Liu S, Qiao X, Wu S, et al. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia[J]. Apoptosis, 2022, 27(11/12): 913-928. DOI: 10.1007/s10495-022-01756-7.
[17]	Carter BZ, Mak PY, Tao W, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition[J]. Haematologica, 2022, 107(1): 58-76. DOI: 10.3324/haematol.2020.260331.
[18]	ClinicalTrials. gov. Study of AZD5991 alone or in combination with venetoclax in relapsed or refractory haematologic malignancies[EB/OL]. (2022-09-23)[2023-05-18]. https://clinicaltrials.gov/study/NCT03218683?tab=history&a=36.
[19]	Wang Y, Wang D, Wang Y, et al. Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia[J]. Neoplasma, 2023, 70(2): 287-293. DOI: 10.4149/neo_2023_221217N1185. pmid: 36812234
[20]	Al-Odat O, von Suskil M, Chitren R, et al. Mcl-1 inhibition: ma-naging malignancy in multiple myeloma[J]. Front Pharmacol, 2021, 12: 699629. DOI: 10.3389/fphar.2021.699629.
[21]	Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies[J]. Cancer Discov, 2018, 8(12): 1582-1597. DOI: 10.1158/2159-8290.CD-18-0387. pmid: 30254093
[22]	ClinicalTrials. gov. AMG 176 first in human trial in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia[EB/OL]. (2016-02-05)[2023-05-18]. https://classic.clinicaltrials.gov/ct2/show/NCT02675452.
[23]	Hormi M, Birsen R, Belhadj M, et al. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML[J]. Eur J Haematol, 2020, 105(5): 588-596. DOI: 10.1111/ejh.13492.
[24]	Liu F, Zhao Q, Su Y, et al. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance[J]. Exp Hematol, 2022, 105: 39-49. DOI: 10.1016/j.exphem.2021.10.006.
[25]	ClinicalTrials. gov. Phase Ⅰ dose escalation study of intravenously administered S64315 in combination with orally administered venetoclax in patients with acute myeloid leukaemia[EB/OL]. (2023-07-25)[2023-08-22]. https://classic.clinicaltrials.gov/ct2/show/NCT03672695.
[26]	Phillips DC, Xiao Y, Lam LT, et al. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)[J]. Blood Cancer J, 2016, 6(3): e403. DOI: 10.1038/bcj.2016.12.
[27]	Ennishi D, Mottok A, Ben-Neriah S, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact[J]. Blood, 2017, 129(20): 2760-2770. DOI: 10.1182/blood-2016-11-747022.
[28]	Lasater EA, Amin DN, Bannerji R, et al. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: results from preclinical models and a phase Ⅰb study[J]. Am J Hematol, 2023, 98(3): 449-463. DOI: 10.1002/ajh.26809.
[29]	Fernández-Marrero Y, Spinner S, Kaufmann T, et al. Survival control of malignant lymphocytes by anti-apoptotic MCL-1[J]. Leukemia, 2016, 30(11): 2152-2159. DOI: 10.1038/leu.2016.213. pmid: 27479182
[30]	Liu T, Lam V, Thieme E, et al. Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner[J]. Clin Cancer Res, 2021, 27(17): 4910-4922. DOI: 10.1158/1078-0432.CCR-21-0464.
[31]	ClinicalTrials. gov. A study of venetoclax and AMG 176 in patients with relapsed/refractory hematologic malignancies[EB/OL]. (2021-12-07)[2023-04-07]. https://classic.clinicaltrials.gov/ct2/show/NCT03797261.
[32]	Brennan MS, Chang C, Tai L, et al. Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use[J]. Blood, 2018, 132(15): 1573-1583. DOI: 10.1182/blood-2018-06-859405. pmid: 30139826
[33]	ClinicalTrials. gov. Safety, tolerability, pharmacokinetics and efficacy of AMG 397 in subjects with selected relapsed or refractory hematological malignancies[EB/OL]. (2023-04-12)[2023-05-18]. https://classic.clinicaltrials.gov/ct2/show/NCT03465540.
[34]	Yi X, Sarkar A, Kismali G, et al. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia[J]. Clin Cancer Res, 2020, 26(14): 3856-3867. DOI: 10.1158/1078-0432.CCR-19-1397. pmid: 31937611
[35]	ClinicalTrials. gov. Phase Ⅰ study of S64315 administred intravenously in patients with acute myeloid leukaemia or myelodysplastic syndrome[EB/OL]. (2022-05-18)[2023-05-18]. https://classic.clinicaltrials.gov/ct2/show/NCT02979366.